利用机器学习（Machine learning）肺癌细胞程序性死亡的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i2.13379
Abstract
肺癌是全球发病率和死亡率最高的恶性肿瘤,具有高度异质性和不良预后。机器学习是一种通过数据驱动模式识别和预测的强大工具。其在肺癌预后标志物开发中展现出巨大潜力,能够从多组学数据中挖掘关键分子,助力精准诊疗。本文综述了肺癌的病理生理学、细胞程序性死亡机制及机器学习在肺癌预后标志物研究中的应用进展。
Keywords
肺癌的治疗方法；细胞程序性死亡；机器学习
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Sung H,Ferlay J,Siegel RL,Laversanne M, Soerjomataram I, Jemal A,et al.2020年全球癌症统计:全球185个国家36种癌症的发病率和死亡率的全球癌症估计.CA:为临床医生准备的癌症杂志,2021,71(3):209-49.
[2] Hosmer DW, Jr.,Lemeshow S.生存分析:在眼科研究中的应用[J].美国眼科杂志,2009,147(6):957-8.
[3] Gawehn E,Hiss JA, Schneider G.药物发现中的深度学习[J].分子信息学,2016;35(1):3-14.
[4] Tibshirani R. The lasso method for variable selection in the Cox model. Statistics in medicine.1997;16(4):385-95.
[5] Chen X,Ishwaran H.用于基因组数据分析的随机森林[J].基因组学,2012,99(6):323-9.
[6] Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al.利用深度神经网络对皮肤癌的皮肤科级别分类[J].自然,2017,542(7639):115-8.
[7] Hao PY,Chiang JH,Chen YD.基于支持向量网络的可能性分类[J].神经网络:国际神经网络协会的官方期刊,2022(149):40-56.
[8] Herbst RS, Morgensztern D, Boshoff C.非小细胞肺癌的生物学和管理[J].自然,2018,553(7689):446-54.
[9] Jordan MI,Mitchell TM.Machine learning:Trends, perspe ctives,and prospects. Science (New York,NY).2015;349(6245):255-60.
[10] Libbrecht MW,Noble WS. Machine learning applications in genetics and genomics. Nature reviews Genetics. 2015;16(6):321-32.
[11] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.Cell.2011;144(5):646-74.
[12] Nicholson AG, Tsao MS,Beasley MB,Borczuk AC,Brambilla E,Cooper WA,et al.2021年世卫组织肺肿瘤分类:自2015年以来研究进展的影响[J].胸腔肿瘤学杂志:国际肺癌研究协会的官方出版物,2022,17(3):362-87.
[13] Hecht SS,Hatsukami DK.Smokeless tobacco and cigare tte smoking: chemical mechanisms and cancer prevention. Natu re reviews Cancer.2022;22(3):143-55.
[14] Kuwabara Y,Kinjo A,Kim H, Minobe R, Maesato H, Higuchi S, et al. Secondhand Smoke Exposure and Smoking Prevalence Among Adolescents. JAMA network open.2023;6(10):e2338166.
[15] Alberg AJ,Samet JM. Epidemiology of lung cancer. Chest.2003;123(1Suppl):21s-49s.
[16] Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.BMJ(Clinical research ed).2005;330(7485):223.
[17] Pope CA, 3rd,Burnett RT,Thun MJ, Calle EE, Krewski D,Ito K,et al.Lung cancer, cardiopulmonary mortality,and longterm exposure to fine particulate air pollution. Jama. 2002; 287(9):1132-41.
[18] Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P.Risk factors for lung cancer worldwide.The European respi ratory journal.2016;48(3):889-902.
[19] Sun S,Schiller JH,Gazdar AF.Lung cancer in never smok ers--a different disease.Nature reviews Cancer.2007;7(10):778-90.
[20] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun tries.CA:a cancer journal for clinicians.2018;68(6):394-424.
[21] Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonarynodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e93S-e120S.
[22] Upadhya P, Ananthraju A, Vadala R, Mohanty Mohapatra M. Endocrine paraneoplastic syndromes in lung cancer: a respi ratory physician's perspective. Advances in respiratory medici ne.2021;89(4):403-12.
[23] Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP,et al.Screening for Lung Cancer With Low-Dose Compu ted Tomography: Updated Evidence Report and Systematic Revi ew for the US Preventive Services Task Force. Jama. 2021;325(10):971-87.
[24] Siravegna G,Marsoni S,Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nature reviewsClinical oncology.2017;14(9):531-48.
[25] Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network:JNCCN.2021;19(3):254-66.
[26] Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamu ra H,Eberhardt WE,et al. The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology:official publicat ion of the International Association for the Study of Lung Cancer.2016;11(1):39-51.
[27] Mok TS, Wu YL,Thongprasert S, Yang CH, Chu DT, Saijo N,et al.Gefitinib or carboplatin-paclitaxel in pulmonary aden ocarcinoma. The New England journal of medicine. 2009;361 (10):947-57.
[28] Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England journal of medicine.2018;378(22):2078-92.
[29] Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell death and differentiation.2018;25(3):486-541.
[30] Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell resear ch.2019;29(5):347-64.
[31] Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends in biochemical scien ces.2017;42(4):245-54.
[32] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death.Cell.2012;149(5):1060-72.
[33] Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science(New York,NY).2022;375 (6586):1254-61.
[2] Hosmer DW, Jr.,Lemeshow S.生存分析:在眼科研究中的应用[J].美国眼科杂志,2009,147(6):957-8.
[3] Gawehn E,Hiss JA, Schneider G.药物发现中的深度学习[J].分子信息学,2016;35(1):3-14.
[4] Tibshirani R. The lasso method for variable selection in the Cox model. Statistics in medicine.1997;16(4):385-95.
[5] Chen X,Ishwaran H.用于基因组数据分析的随机森林[J].基因组学,2012,99(6):323-9.
[6] Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al.利用深度神经网络对皮肤癌的皮肤科级别分类[J].自然,2017,542(7639):115-8.
[7] Hao PY,Chiang JH,Chen YD.基于支持向量网络的可能性分类[J].神经网络:国际神经网络协会的官方期刊,2022(149):40-56.
[8] Herbst RS, Morgensztern D, Boshoff C.非小细胞肺癌的生物学和管理[J].自然,2018,553(7689):446-54.
[9] Jordan MI,Mitchell TM.Machine learning:Trends, perspe ctives,and prospects. Science (New York,NY).2015;349(6245):255-60.
[10] Libbrecht MW,Noble WS. Machine learning applications in genetics and genomics. Nature reviews Genetics. 2015;16(6):321-32.
[11] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.Cell.2011;144(5):646-74.
[12] Nicholson AG, Tsao MS,Beasley MB,Borczuk AC,Brambilla E,Cooper WA,et al.2021年世卫组织肺肿瘤分类:自2015年以来研究进展的影响[J].胸腔肿瘤学杂志:国际肺癌研究协会的官方出版物,2022,17(3):362-87.
[13] Hecht SS,Hatsukami DK.Smokeless tobacco and cigare tte smoking: chemical mechanisms and cancer prevention. Natu re reviews Cancer.2022;22(3):143-55.
[14] Kuwabara Y,Kinjo A,Kim H, Minobe R, Maesato H, Higuchi S, et al. Secondhand Smoke Exposure and Smoking Prevalence Among Adolescents. JAMA network open.2023;6(10):e2338166.
[15] Alberg AJ,Samet JM. Epidemiology of lung cancer. Chest.2003;123(1Suppl):21s-49s.
[16] Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.BMJ(Clinical research ed).2005;330(7485):223.
[17] Pope CA, 3rd,Burnett RT,Thun MJ, Calle EE, Krewski D,Ito K,et al.Lung cancer, cardiopulmonary mortality,and longterm exposure to fine particulate air pollution. Jama. 2002; 287(9):1132-41.
[18] Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P.Risk factors for lung cancer worldwide.The European respi ratory journal.2016;48(3):889-902.
[19] Sun S,Schiller JH,Gazdar AF.Lung cancer in never smok ers--a different disease.Nature reviews Cancer.2007;7(10):778-90.
[20] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun tries.CA:a cancer journal for clinicians.2018;68(6):394-424.
[21] Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonarynodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e93S-e120S.
[22] Upadhya P, Ananthraju A, Vadala R, Mohanty Mohapatra M. Endocrine paraneoplastic syndromes in lung cancer: a respi ratory physician's perspective. Advances in respiratory medici ne.2021;89(4):403-12.
[23] Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP,et al.Screening for Lung Cancer With Low-Dose Compu ted Tomography: Updated Evidence Report and Systematic Revi ew for the US Preventive Services Task Force. Jama. 2021;325(10):971-87.
[24] Siravegna G,Marsoni S,Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nature reviewsClinical oncology.2017;14(9):531-48.
[25] Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network:JNCCN.2021;19(3):254-66.
[26] Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamu ra H,Eberhardt WE,et al. The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology:official publicat ion of the International Association for the Study of Lung Cancer.2016;11(1):39-51.
[27] Mok TS, Wu YL,Thongprasert S, Yang CH, Chu DT, Saijo N,et al.Gefitinib or carboplatin-paclitaxel in pulmonary aden ocarcinoma. The New England journal of medicine. 2009;361 (10):947-57.
[28] Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England journal of medicine.2018;378(22):2078-92.
[29] Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell death and differentiation.2018;25(3):486-541.
[30] Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell resear ch.2019;29(5):347-64.
[31] Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends in biochemical scien ces.2017;42(4):245-54.
[32] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death.Cell.2012;149(5):1060-72.
[33] Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science(New York,NY).2022;375 (6586):1254-61.
Copyright © 2025 翁妃萱
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
